05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not

Eliminate the gap between R&D and cGMP manufacturing with mirrored environments. This strategy bypasses clinical transfer delays to speed up IND submissions and improve patient access timelines.

High-strength synthetic gene promoters can enhance expression stability and titers. Discover how these vector technologies support efficient biomanufacturing without compromising product quality.

Small early-stage decisions often lead to hidden variability at scale. Learn why standardization is essential for long-term stability, reproducibility, and maintaining regulatory confidence.

Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality.

Uncover how integrated custom media solutions can accelerate the path to manufacturing success, supporting both clients with established formulations and those seeking new designs.

Launching nucleic acid therapies requires specialized formulation expertise. Implement rigorous analytical strategies to ensure product stability and quality throughout the development cycle.

Achieve inducible expression in as little as four to six weeks. Utilizing pre-engineered landing pads significantly reduces the time and effort required for donor plasmid development phases.

Expedited cell therapy pathways demand early, reliable analytical development to ensure robust data, regulatory confidence, and smooth transitions from discovery through clinical stages without costly delays.

Pittsburgh's industrial roots and growing biotech hub unite to scale advanced therapies through new purpose‑built biomanufacturing, automation, and workforce development.

Plasmid engineering and process development boosted viral titer 12.5×, eliminating manufacturing bottlenecks and enabling an on‑time regulatory submission for the cell therapy program.